A Two-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of ID-085 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs ID-085 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Idorsia Pharmaceuticals
- 18 Dec 2018 Status changed from recruiting to completed.
- 16 Jan 2018 Status changed from not yet recruiting to recruiting.
- 02 Jan 2018 Planned initiation date changed from 22 Dec 2017 to 31 Jan 2018.